Equivet TZ en es it fr

Equivet TZ Brand names, Equivet TZ Analogs

Equivet TZ Brand Names Mixture

  • No information avaliable

Equivet TZ Chemical_Formula


Equivet TZ RX_link


Equivet TZ fda sheet

Equivet TZ msds (material safety sheet)

Equivet TZ Synthesis Reference

No information avaliable

Equivet TZ Molecular Weight

192.258 g/mol

Equivet TZ Melting Point

246-266 oC

Equivet TZ H2O Solubility

1.07E+004 mg/L

Equivet TZ State


Equivet TZ LogP


Equivet TZ Dosage Forms

400 mg and 600 mg tablets for oral administration

Equivet TZ Indication

For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

Equivet TZ Pharmacology

Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.

Equivet TZ Absorption

Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.

Equivet TZ side effects and Toxicity

The oral LD50 of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.

Equivet TZ Patient Information

Equivet TZ Organisms Affected

Humans and other mammals